CliffBio
small molecule

FUSILEV

LEVOLEUCOVORIN CALCIUM

Loss of exclusivity—loss of exclusivity
CompanyAcrotech Biopharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameFUSILEV
Active ingredientLEVOLEUCOVORIN CALCIUM
StrengthEQ 50MG BASE/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalMarch 2008
Marketing statusDISCN

More from Acrotech Biopharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

FUSILEV patent cliff — loss of exclusivity — | CliffBio